Overview

A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer

Status:
Not yet recruiting
Trial end date:
2025-01-07
Target enrollment:
Participant gender:
Summary
This trial is a Phase II study. The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of AK112 with or without AK117 in participants with metastatic colorectal cancer who are not suitable for surgery.
Phase:
Phase 2
Details
Lead Sponsor:
Akeso
Treatments:
Bevacizumab
Capecitabine
Fluorouracil
Irinotecan
Leucovorin
Oxaliplatin